Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6406

12 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)

Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)
Chemical structure of duloxetine hydrochloride, shown as a molecular diagram illustrating the arrangement of atoms and bonds including a thiophene ring, naphthalene ring, and functional groups characteristic of duloxetine HCl.*
FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)
This Kaplan-Meier estimator method chart shows the proportion of patients with relapse over time (days) from randomization, comparing Duloxetine treatment to placebo. The x-axis represents time in days, and the y-axis shows the proportion of patients relapsing. The Duloxetine group displays a lower relapse proportion compared to the placebo group over approximately 200 days.*
FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)
A Kaplan-Meier plot showing the proportion of patients with relapse over time in days from randomization. The graph compares two treatments: placebo (dashed line) and Duloxetine (solid line), with a higher relapse proportion in the placebo group over approximately 250 days.*
FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)
A line graph displaying the percentage of patients improved versus the percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg QD, and a placebo group, showing trends of patient improvement across increasing pain relief percentages up to 100%.*
FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)
A line graph depicting the percentage of patients improved relative to the percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The x-axis represents percent improvement in pain from 0% to 100%, and the y-axis shows the percentage of patients improved, ranging from 0% to 100%. The graph shows higher patient improvement percentages for both Duloxetine dosing regimens compared to placebo across pain improvement levels.*
FDA Label Image

Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)

Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)
A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. Three lines represent Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing patient improvement trends over varying pain improvement percentages.*
FDA Label Image

Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)

Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)
A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine at 120 mg twice daily, Duloxetine at 60 mg once daily, and placebo. The graph shows multiple lines representing each treatment and placebo, illustrating patient response rates across different pain improvement thresholds.*
FDA Label Image

Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)

Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)
A line graph depicting the percentage of pediatric patients aged 13 to 17 years with Juvenile Fibromyalgia Syndrome who achieved various levels of pain relief at week 12. The X-axis represents percent improvement in pain from baseline, while the Y-axis shows the percentage of patients improved. Two groups are plotted: Duloxetine 60 mg once daily and placebo, showing higher pain relief percentages for the Duloxetine group across the improvement levels.*
FDA Label Image

Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)

Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60/120 mg once daily. The graph plots two curves: one for placebo and one for Duloxetine, showing patient response across different pain improvement thresholds from greater than 0% to 100%.*
FDA Label Image

Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)

Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)
A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF). Two lines represent placebo and Duloxetine 60 mg once daily, showing differences in patient improvement across various pain reduction thresholds.*
FDA Label Image

Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)

Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)
A line graph comparing the percentage of patients improved over various levels of percent improvement in pain from baseline (BOCF). Two datasets are shown: one for placebo and another for Duloxetine 60/120 mg once daily, with Duloxetine consistently showing higher patient improvement percentages across the pain improvement spectrum.*
FDA Label Image

Label Image (Lbl500906406)

Label Image (Lbl500906406)
Duloxetine 20 mg delayed-release capsules label from A-S Medication Solutions. The label indicates oral dosage form with 90 capsules per package. It specifies storage instructions at 77 degrees Fahrenheit. The NDC is 50090-6406-0, and the label is marked as prescription only (RX).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.